Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30515644 | 1.00 | DHFR (0.45) | DHFRMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28066916 | 0.87 | PDE8B (0.39) | DHFRMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28066962 | 0.79 | PDE8B (0.40) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18109476 | 0.76 | TNK2 (0.39) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1368683 | 0.76 | MCL1 (0.39) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1775677 | 0.75 | — | — | |
| SCHEMBL2634024 | 0.75 | DHFR (0.42) | DHFR | |
| SCHEMBL1318801 | 0.74 | CDK2 (0.43) | — | |
| SCHEMBL30018228 | 0.73 | TNK2 (0.42) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2513471 | 0.72 | TNK2 (0.40) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514779-A | 2, 4-disubstituted-5-fluoropyrimidine derivative and preparation method and application thereof | 中南大学 | 2023-08-01 | — | — | CN | claimed |
| WO-2007085540-A1 | 1H-INDAZ0L-4-YL-2 , 4-PYRIMIDINEDIAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | WO | claimed |
| US-12630535-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-21 | — | — | US | disclosed |
| CN-116514779-A | 2, 4-disubstituted-5-fluoropyrimidine derivative and preparation method and application thereof | 中南大学 | 2023-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | DHFR 4034/4885MEN1 2787/4885CYP1A2 4823/4885 |
| US-12630535-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | DHFR 4795/4885MEN1 3260/4885CYP1A2 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.